Previous studies have shown that patients with N2 downstaging after neoadjuvant chemotherapy can achieve a more favorable survival time.20,21 In this study, we sought to assess the N2 downstaging rate of patients with III-N2 NSCLC with EGFR mutation who received chemotherapy combined with the first-generation TKI. Here, EGFR is linked to non-small cell lung carcinoma.